More recently a phase-II trial evaluating [177Lu]PSMA-617 in the setting of metastatic prostate cancer used lesion 68Ga-PSMA-11 uptake that was significantly greater than liver [35]. Here, FOLH1 is linked to metastatic prostate carcinoma.